Log In
Print
BCIQ
Print
Print this Print this
 

VB-111

  Manage Alerts
Collapse Summary General Information
Company VBL Therapeutics Ltd.
DescriptionAnti-angiogenic therapy consisting of a non-replicating adenovirus vector with a modified murine pre-proendothelin promoter (PPE-1-3x) developed using Vascular Targeting System (VTS) technology
Molecular Target
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today